Navigation Links
UF scientists to work with German firm in prostate cancer treatment research
Date:6/18/2008

GAINESVILLE, Fla. University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.

CureVac which specializes in the therapeutic application of messenger RNA, a biomolecule that transfers genetic information from nuclear DNA to cellular protein production machinery is developing a stabilized mRNA-derived vaccine for treatment of prostate cancer.

UF researchers will conduct a phase 1/2 clinical trial of the therapy in patients from the United States with metastatic prostate cancer who no longer respond to hormone therapy. Both institutions hope the initial collaboration will result in a better biologic product to work with in the second phase of the clinical trial.

"The agreement with the University of Florida represents our first step to the U.S. as the world's leading pharmaceutical marketplace with world-class academic institutions for research and development," said Thomas Lander, M.D., managing director and chief medical officer of CureVac.

In what will be the first direct-application trial of its kind in the United States, researchers plan to test molecules that have shown the potential to stimulate an immune response against tumors when injected into the skin, potentially providing an alternative therapy for this form of cancer.

"Several studies support the therapeutic potential of mRNA for the treatment of cancer," said Johannes Vieweg, M.D., a professor and chairman of UF's department of urology who is a member of CureVac's scientific advisory board. "This, however, will be the first clinical trial in the U.S. to use the direct application route by injecting modified mRNA into the skin."

UF urology researchers have treated more than 500 patients using RNA-based dendritic cells, which have been used in vaccines to treat the cancer, but these cells are difficult to manufacture and are often limited in quantity. Researchers hope to discover whether CureVac's technology may be an equivalent or more effective therapy to stimulate tumor response, Vieweg said.

"Our extensive experience and expertise in immunological monitoring and vaccine development are of value to companies such as CureVac, I believe, making us an attractive partner to work with," Vieweg said.

The Prostate Cancer Foundation estimates nearly 200,000 men will be diagnosed with prostate cancer in the United States in 2008. Treatment options generally include surgery or radiation if patients are diagnosed at an early stage. Hormone therapy is often used when cancer has spread beyond the prostate gland.

The proposed clinical trial is expected to begin in 2009. In the first phase of the trial, researchers will seek to define the optimal dose level of the therapy, as well as establish safety and evaluate improvements needed for the regimen. A European clinical trial is also planned.


'/>"/>

Contact: Melissa M. Thompson
thompsmelissa@gmail.com
352-273-5810
University of Florida
Source:Eurekalert

Related medicine news :

1. Scientists from Granada drastically reduce the wait time for new teeth implant
2. Possible link between different forms of epilepsy found by Carnegie Mellon scientists
3. Scientists Discover Protein Involved in Fat Production
4. Twenty of Americas Most Promising Scientists Selected as 2008 Pew Scholars in the Biomedical Sciences
5. QBI neuroscientists make Alzheimers disease advance
6. EPA scientists recognized with prestigious honor
7. 2collab Survey Reveals That Scientists and Researchers are "All Business" With Social Applications
8. Scientists ID Brain Pathway That Stops Seizures
9. Scientists ID Gene Regulating Blood Glucose Levels
10. South African scientists access European research via EMBC agreement
11. Zebrafish enable scientists to study the migration of neurons that enable sexual maturity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: